Rivaroxaban label update for extended VTE prevention

Br J Cardiol 2017;24:135 Leave a comment
Click any image to enlarge

The European Commission (EC) has approved an update to the label of rivaroxaban (Xarelto®, Bayer) to include a 10 mg once daily dose for the extended prevention of recurrent venous thromboembolism (VTE). This label update applies to patients who have already received at least six months of standard anticoagulation therapy, and provides clinicians with an additional treatment option alongside the 20 mg once daily dose already licensed in this indication.

Heart failure - BJC Learning programme
For healthcare professionals only

Current treatment recommendation for the prevention of recurrent VTE is anticoagulation therapy for three months or longer, depending on the balance between the risk of recurrent VTE and the risk of bleeding. However, the risk of patients with unprovoked VTE or with ongoing risk factors experiencing a second event is up to 10% in the first year if treatment is stopped. More than 25,000 people in the UK die from VTE every year.

More news in this issue:

NICE publishes updated familial hypercholesterolaemia guidance

REDUCE shows non-inferiority of short versus long DAPT in acute coronary syndrome

Primary Care Cardiovascular Society announces its relaunch

New series on insights from the Bradford Healthy Hearts project

Cardiff Met launches stroke research hub

New test hopes to boost med school recruitment

European Society of Cardiology congress, the world’s biggest gathering of heart specialists, returns to London in 2021

Anticoagulation group rebrands and partners with the BJC